Goldman Sachs
PLRX icon

Goldman Sachs’s Pliant Therapeutics PLRX Stock Holding History

Goldman Sachs’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Sell
208,585
-388,252
-65% -$473K ﹤0.01% 6119
2026
Q1 		$752K Buy
596,837
+319,971
+116% +$404K ﹤0.01% 5304
2025
Q4 		$338K Sell
276,866
-278,210
-50% -$418K ﹤0.01% 5807
2025
Q3 		$822K Sell
555,076
-41,622
-7% -$63.5K ﹤0.01% 5170
2025
Q2 		$692K Buy
596,698
+120,821
+25% +$171K ﹤0.01% 4957
2025
Q1 		$642K Buy
475,877
+29,177
+7% +$177K ﹤0.01% 5029
2024
Q4 		$5.88M Buy
446,700
+99,303
+29% +$1.36M ﹤0.01% 3293
2024
Q3 		$3.89M Buy
347,397
+134,159
+63% +$1.68M ﹤0.01% 3570
2024
Q2 		$2.29M Sell
213,238
-289,333
-58% -$3.73M ﹤0.01% 3820
2024
Q1 		$7.49M Buy
502,571
+115,325
+30% +$1.9M ﹤0.01% 2745
2023
Q4 		$7.01M Buy
387,246
+222,132
+135% +$3.38M ﹤0.01% 2853
2023
Q3 		$2.86M Sell
165,114
-60,909
-27% -$1.06M ﹤0.01% 3474
2023
Q2 		$4.1M Sell
226,023
-37,490
-14% -$887K ﹤0.01% 3270
2023
Q1 		$7.01M Buy
263,513
+116,156
+79% +$3.31M ﹤0.01% 2739
2022
Q4 		$2.85M Buy
147,357
+44,791
+44% +$936K ﹤0.01% 3654
2022
Q3 		$2.14M Sell
102,566
-328,658
-76% -$6.29M ﹤0.01% 3924
2022
Q2 		$3.45M Buy
431,224
+288,539
+202% +$1.85M ﹤0.01% 3541
2022
Q1 		$1M Buy
142,685
+45,057
+46% +$460K ﹤0.01% 4816
2021
Q4 		$1.32M Buy
97,628
+64,562
+195% +$1.03M ﹤0.01% 4613
2021
Q3 		$558K Buy
33,066
+7,660
+30% +$163K ﹤0.01% 5131
2021
Q2 		$739K Buy
25,406
+10,689
+73% +$333K ﹤0.01% 4977
2021
Q1 		$579K Sell
14,717
-3,348
-19% -$109K ﹤0.01% 5016
2020
Q4 		$410K Buy
+18,065
New +$453K ﹤0.01% 4727
2020
Q3 		– Sell
-45,000
Closed -$1.46M – 5502
2020
Q2 		$1.46M Buy
+45,000
New +$1.19M ﹤0.01% 3688

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Goldman Sachs's PLRX Position: Q2 2026 in Review

Goldman Sachs reduced its Pliant Therapeutics (PLRX) stake by 65% in Q2 2026, selling an estimated $473K and leaving 208,585 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #6119.

Goldman Sachs first reported a position in PLRX in Q2 2020 and has held it in 24 quarters since. The position peaked at $7.49M in Q1 2024. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Goldman Sachs held 208,585 shares of Pliant Therapeutics worth $238K as of Q2 2026.
  • Goldman Sachs sold 388,252 Pliant Therapeutics shares in Q2 2026, an estimated $473K.
  • Pliant Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6119 holding.
  • Goldman Sachs first reported a position in Pliant Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Goldman Sachs's Pliant Therapeutics position peaked at $7.49M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.